RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets

Author(s): Laura de Ramon, Marta Jarque, Elia Ripoll, Oriol Bestard, Josep M. Grinyo, Juan Torras.

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 30 , 2016

Submit Manuscript
Submit Proposal

Abstract:

Background: Ischemia reperfusion injury is an important pathophysiological process in many fields such as transplantation, stroke, atherosclerosis, trauma and myocardial infarction. Recent advances in gene silencing may help to reduce ischemic effects, targeting molecules related to this pathological process. Methods and results: Here, we review the different silencing approaches in ischemic injury, highlighting the role of co-stimulatory molecules in renal transplantation. Conclusion: Gene silencing appears as a new strategy to prevent the inflammation and injury associated with ischemia.

Keywords: Ischemia, siRNA, gene silencing, CD40.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 22
ISSUE: 30
Year: 2016
Page: [4651 - 4657]
Pages: 7
DOI: 10.2174/1381612822666160719103955
Price: $58

Article Metrics

PDF: 27
HTML: 4
EPUB: 1
PRC: 1